Moloney Securities Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Moloney Securities Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,400	Closed	-$192K	–	445
2022 Q4	$192K	Buy	+13,400	New	+$211K	0.04%	362
2022 Q3	–	Sell	-8,350	Closed	-$237K	–	393
2022 Q2	$237K	Sell	8,350 -2,000	-19%	-$63.4K	0.06%	312
2022 Q1	$365K	Sell	10,350 -100	-1%	-$3.35K	0.07%	261
2021 Q4	$438K	Sell	10,450 -7,300	-41%	-$296K	0.07%	263
2021 Q3	$871K	Buy	+17,750	New	+$866K	0.16%	173

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Moloney Securities Asset Management's MRVI Position: Q1 2023 in Review

Moloney Securities Asset Management sold out of Maravai LifeSciences (MRVI) in Q1 2023, closing a stake of 13,400 shares — an estimated $192K sold.

Moloney Securities Asset Management first reported a position in MRVI in Q3 2021 and held it in 5 quarters. The position peaked at $871K in Q3 2021. 219 funds tracked by Wall St. Rank hold MRVI as of Q1 2023.

Moloney Securities Asset Management reported no remaining Maravai LifeSciences position as of Q1 2023 after selling out during the quarter.
Moloney Securities Asset Management sold 13,400 Maravai LifeSciences shares in Q1 2023, an estimated $192K.
Moloney Securities Asset Management first reported a position in Maravai LifeSciences in Q3 2021 and held it in 5 quarters.
Moloney Securities Asset Management's Maravai LifeSciences position peaked at $871K in Q3 2021.
219 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2023.

Based on Moloney Securities Asset Management's 13F filing for Q1 2023, filed 12 May 2023.